Publicly available RNA-seq data from human A375 melanoma cells treated with the clinically approved DHODH inhibitor teriflunomide 38 corroborated our findings, as teriflunomide caused a rapid (within 12 hours) and duration-dependent increase in MHC-I/II and APP transcript levels (Fig 1E). Here, APP is linked to melanoma.